This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Imbruvica
  • /
  • A Randomized, Multicenter, Open Label, Phase 3 Stu...
Clinical trial

A Randomized, Multicenter, Open Label, Phase 3 Study of Acalabrutinib (ACP-196) in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Alone in Subjects With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)

Read time: 2 mins
Last updated:30th Apr 2016
Identifier: NCT02735876
This study is evaluating the efficacy of acalabrutinib in combination with rituximab (Arm 1) versus ibrutinib (Arm 2) versus acalabrutinib (Arm 3) for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Category Value
Date last updated at source 2016-05-12
Study type(s) Interventional
Study start date 2016-05-01
Estimated primary completion date 2020-06-01

View full details